Ceapro Inc V.CZO

Next week - January 18

[prophetoffactz]

January 18, 2023 is with Q4 completed and going on 1 year into the new deal with Symrise that anticipated acceleration. It is approximately 6 months since the addition of Sigrun Watson as CRO. It is approximately 1 month from Health Canada approval for the avenanthramides clinical trial. It is over 5 months since the expansion of the agreement with McMaster paving the way for a potential Phase I clinical trial. It's over 2 months since the launch of the scale-up of PGX. Three months ago CZO also released the intestinal bioavailability study results from the University of Alberta. Earlier it had said,  

• "Of interest, the size of PGX processed YBG particles (around 5 microns) would allow them to be “swallowable” by macrophages that would carry them to remote sites in the body. Thus, the loading of drugs onto PGX YBG is currently under further investigation, since numerous research studies suggest that YBG cells being swallowed by macrophages could be utilized as “Trojan Horses” to carry bioactives (potentially CoQ10, antioxidants, pain killers or potent pharmaceutical drugs) into the body to the target tissue."

Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event

V.CZO | 25 minutes ago

Live video webcast on Wednesday, January 18th at 3:00 PM ET

EDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and Chief Executive Officer of Ceapro, will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023 at 3:00 PM ET.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (ceapro.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): [phone]
E: [e-mail]

Issuer:

Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Tags:

[Ciao]

Given that this is a home bred investor conference by JTC, the reach will be mainly limited to the network of investors JTC has engaged. As I have been receiving emails from JTC on other companies using JTC for IR, the audience if interested would already know the Ceapro name. Let's see if the approach is to provide existing shareholders and those famiilar with the story a solid update on all

[prophetoffactz]

:"Let's see if the approach is to provide existing shareholders and those famiilar with the story a solid update on all the initiatives in the R&D pipeline and what could be catalsysts for the stock this year. That should be 70 - 80% of the emphasis of the presentation. The other portion could be a quick summary or walk through of the same slides outlining their business to new

[boazklinghorn]

"Echeme un hueso" as we say here in sunny Mex. It will be the same nonsense goboldygook franglish blather Gilles has been spluttering ever since I started watching CZO 4 years ago. Lucky for existing shareholders and newbies alike Jenene will ask some deep probing questions to try and give the market an indepth idea of the company.  Haha NOT. 

[prophetoffactz]

It would also be nice to see the data curves over 24 hours and not just data points at 8 hours or 12 hours in selective instances. "In the summary report of the project, Dr. Vine concludes, “This in vivo pilot study shows that following 8 hours, the 5.8% iYBG and 20% iAL CoQ10 formulations have increased bioavailability of CoQ10 up to 2-3 fold higher compared to food grade CoQ10 in

[prophetoffactz]

The presentation next Wed. will be the first for Gilles to discuss the bioavailability results from the University of Alberta that justified the PGX scale-up decision subsequently. The CoQ10 market has been forecast to be a billion dollar market. CZO billed the bioavailability results as:   "Superior bioavailability data further confirm potential for the development of first-in